Table 5 Treatment characteristics of respondents with Crohn's disease and Ulcerative colitis.
From: A national survey on the patterns of treatment of inflammatory bowel disease in Canada
Treatments | CD n (%) | UC n (%) | 95% CI for difference (P value) |
|---|---|---|---|
PO 5ASA | 956 (54%) | 672 (74%) | -23.7 to -16.4 (<0.001) |
Topical Steroids/5ASA | 183 (10%) | 391 (43%) | -36.1 to -29.1 (<0.001) |
PO Steroids | 623 (35%) | 259 (28%) | 2.8 to 10.2 (0.001) |
6 MP/Azathioprine | 424 (24%) | 109 (12%) | 8.9 to 14.7 (<0.001) |
IV Steroids | 90 (5%) | 41 (5%) | -1.1 to 2.2 (0.571) |
Infliximab | 99 (6%) | 7 (1%) | 3.6 to 6.0 (<0.001) |